Zymo Research Europe GmbH

Name ›

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

Request for ›

Further Collaborations YUMAB GmbH Science Campus Braunschweig-Süd

Inhoffenstr. 7 38124 Braunschweig Germany Alexander Ehm +49-531-481170-0 info@yumab.com www.yumab.com

I Q

27 2012 S1, S2

| Fully human antibody discovery & lead development | Antibody Libraries | Engineering & Humanisation | Professional R&D services (CRO) | Optimised conditions for start-up, biotech & biopharma companies | Flexible entry & exit points at any project stage | Partnered innovation

YUMAB seeks clients & partners in biopharma, biotech & diagnostic industry as well as partners with innovative research projects, who need a reliable partner in human antibody development

YUMAB is a contract developer of fully human antibodies for the global biotechnological and biopharmaceutical industry. Starting in 2012 with the goal to bridge the gap between innovative research and novel therapies, the company has become an important driver of the general trend in immunotherapy toward the use of fully human antibodies. The versatile technology platform combined with a longstanding and proven expertise makes YUMAB the partner of choice for the development of novel antibodies for therapeutic applications, diagnostics, or vaccines tailored to the clients’ needs. R&D projects customised with flexible entry and exit points at any stage and for any immunotherapeutic strategy appeal to start-ups, biotech, or biopharma companies. With the starting pandemic early 2020, YUMAB collaborated with the University Braunschweig and other partners to develop antibodies against SARS-CoV-2. The promising results ended in the YUMAB spin-out CORAT Therapeutics GmbH (see seperate company profile on page 68 ), founded in May 2020. The collaboration and its success were honored with the Innovation Award of the state of Lower Saxony at the end of September 2020. Currently, the antibody drug candidate COR-101 is in the clinical phase Ib/II, which is being conducted at five study centers in Germany. Here, COR-101 is being tested in hospitalized patients, in particular to assess safety, tolerability, and efficacy.

The YUMAB® platform: fast & reliable translation from innovation to drugs

The YUMAB® R&D platform delivers fully human antibodies, the closest to natural germline among those on the market, using fast and reliable in vitro discovery technologies. The company’s highly diverse, human antibody libraries contain 1011 natural antibody sequences and specificities to all types of antigens. Unlike animalderived, chimeric, humanised, or synthetic antibodies, each YUMAB® antibody sequence has been shaped in the human body, which maximises epitope diversity and overcomes restriction by in vivo immune responses while minimising immunogenicity and potential adverse effects in clinical development.

Our advanced in vitro selection technology is also efficient for rare and difficult target antigens and allows pre-design of epitope specificity, interspecies X-reactivity, affinity, stability, and other properties early in the discovery and development process. First antibody candidates are identified swiftly within a few weeks and are highly developable into all types of antibody drug formats such as full-length IgGs, Fabs, scFvs, bispecifics, CARs, fusion proteins, and ADCs.

YUMAB provides tailored service and partnering concepts to jump-start translation from research innovation to drug development with affordable entry costs, flexible licensing options, and no additional third-party obligations.

YUMAB at a glance

Human antibody discovery platform › Natural fully human libraries for low immunogenicity › Optimised in vitro selection to address difficult targets › Rapid discovery within weeks

Direct link to lead development › Advanced antibody lead development & optimisation › All antibody drug formats, all disease areas › Robust & fast process with high success rates

YUMAB® platform › Fully integrated discovery & development platform from target to optimised lead › Customised project plans with flexible entry & exit points › Smooth translation from bench to bedside

Flexible services, collaborations & partnering › Contract R&D as fee-for-service & flexible licence options › No technology access fees › Partnered collaboration to translate research innovation into drug development

FULLY HUMAN ANTIBODY

DISCOVERY PLATFORM

Name ›

Address/P.O. Box › Postal Code/City › Country › Telephone › Fax › Email › Website › Number of Employees › Founded (year) ›

Areas of Activity ›

Zymo Research Europe GmbH

Mülhauser Str. 9 79110 Freiburg Germany +49-761-60068-71-0 +49-761-60068-71-20 info@zymoresearch.de www.zymoresearch.de > 20 1994

| Microbiomics | Epigenetics | Sample Collection

Vision and Mission

From its birthplace in a small garage in Orange, California, to the industry leader it is today, Zymo Research has been led by the vision to have a positive impact in the biomedical field and to contribute to the greater good of humanity. That vision touches every aspect of Zymo Research and has guided the company’s growth, culture and creation of the most innovative and valuable biomedical tools and services since 1994.

Now, Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging NextGene Sequencing space. While the company provides some of the most technologically advanced and reliable products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”

Epigenetics

As the industry leader in epigenetics, Zymo Research offers a complete product portfolio and analytic services for epigenetics research. Zymo Research’s suite of EZ DNA Methylation™ products are of highest quality, the most trusted, and most cited technologies for bisulfite conversion. Zymo Research is committed to enhance the epigenetic studies by providing researchers of every discipline with quality products needed to answer the big questions in molecular biology research today.

One of the special services of Zymo Research is the myDNAge™ test including the analytical service which is based on Next-Gene sequencing and is used to determine the biological age. The DNAge™ technology is based on the epigenetic aging clock (Horvath’s Clock) which analyzes DNA methylation patterns and provides information about the influence of lifestyle or disease on the aging process.

Microbiomics

The field of microbiomics has been developing rapidly in recent years and still there is a lack of standardisation and reproducibility of data in different labs. To address the fundamental challenges, Zymo Research is leading the development of new microbiome-grade tools in this field. These include the first commercially available microbiome reference materials, the first DNA extraction kit designed to ensure non-biased cell lysis, and the first cold-free and unbiased method to preserve microbial samples.

Zymo Research’s goal is to eliminate bias across microbiomics workflows and provides a complete pipeline from collection to analysis. The standardized workflows improve the reproducibility of data across labs.

Sample Collection on Earth and in Space

Zymo Research received recognition from NASA for their cooperation and dedication in the development of a unique sample collection tube to support human research aboard the International Space Station (ISS). A custom solution was made for NASA’s research, with DNA/RNA Shield™ to preserve microbial metatranscriptomic profiles in space until missions are complete, and samples can be brought back to earth for analysis. DNA/RNA Shield™ enables superior stabilization of nucleic acids and allows convenient and safe shipment of samples at room temperature worldwide and beyond.

© Swiss Biotech Association SWISS BIOTECH DAY

...ONE BIOTECH CLUSTER

“WHITE BIOTECHNOLOGY” WORKING GROUP

Leading chemical companies are exploring the opportunities that have been opened up by modern biotechnology, especially in the field of “white” or industrial biotechnology. And they are also applying these technologies, wherever it makes sense. The SBA takes such initiatives seriously and has formed a working group specifically dedicated to white biotechnology. The Swiss Industrial Biocatalysis Consortium is an important partner in this effort. The group includes leading multinational companies that support white biotechnology as a pillar of economic growth. The planned activities are in agreement with OECD In partnership with the Swiss Biotechnet (see pages 14/15) the SBA develops training programmes and useful support tools for the industry. It is of importance that the industry specifies its training needs so that the academic side can create tailor-made education. This strategy ensures that the industry gets the right workforce with the right education. The SBA profits from the marketing alliance “Swiss Biotech” (see box) in a multiplied form. Thanks to Swiss Biotech, the

sector is internationally visible. The project-specific participating companies (most of them young and internationally less savvy) find a comprehensive partner which is helping to put them in the public window. The participating Life Science Regions are important internal carriers of the dynamics in the Biotech sector, thus enhancing the common understanding of the industry. This and more knowledge is brought into Europa Bio, the European Biotech Association, where the SBA is an active member. Sign in on our website at www.swissbiotechday.ch and stay updated about any news. Main sponsors:

Sponsors:

Domenico Alexakis is Executive Director of the Swiss Biotech Association.

SWISS BIOTECH...

...is an alliance of four leading Biotech regions of Switzerland (Bio Alps, BioPolo Ticino, Basel Area May 2-3, 2022 and Greater Zurich Area). They have combined efforts to streamline interests of the national biotech sector. The SWX Swiss Exchange holds a leadingCongress Center Basel position in terms of lifescience listings and offers companies from that industry – be they located in Switzerland or abroad – access to an internationally recognised financial marketplace. The initiative was co-founded by the SBA which also manages Organized by: the executive office of Swiss Biotech.

@For further information please visit www.swissbiotechassociation.ch www.swissbiotech.org

ISBN 978-3-928383-83-7